The global market size of ovarian cancer in 2007 was valued
at US$2.1b
• This is estimated to grow to US$3.6b by 2010
• Each year 73,000 women are diagnosed with ovarian cancer
in the US, Europe, Australia and Japan
• Of this number only 10-20% survive beyond 5 years
• A maintenance style treatment like CVac™ would be the first
of its type in the market and would initially aim to take 10% of
this ovarian cancer market
• A 10% market share equates to approximately US$360m
• Cvac™ has indications across a multitude of cancers
http://www.primabiomed.com.au/projects/prodDocuments/PRR%20ASX%20Investor%20Presentation%2021April%2009.pdf
future earning, page-17
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |